Endocrine Toxicity and Outcomes in Patients With Metastatic Malignancies Treated With Immune Checkpoint Inhibitors.

Suleiman I Al AshiBicky ThapaMonica FloresRamsha AhmedShab E Gul RahimMaryam AmirMohammad AlomariPravallika ChadalavadaShannon L MorrisonJames Frank BenaAleck HercbergsOssama LashinHamed Daw

Published in: Journal of the Endocrine Society (2021)

In the adult population with metastatic cancer receiving treatment with ICI, irEEs development may predict tumor response to immunotherapy and a favorable prognosis. Ipilimumab use, combination ICI therapy, and melanoma are associated with a higher incidence of irEEs.

Keyphrases

papillary thyroid
squamous cell carcinoma
small cell lung cancer
risk factors
squamous cell
stem cells
young adults
combination therapy
newly diagnosed
replacement therapy
mesenchymal stem cells
skin cancer
bone marrow
cell therapy
basal cell carcinoma